
Listen as Dr. Donna Culton discusses the importance of crosstalk between autoantibodies and type 2 inflammation in the development of bullous pemphigoid.

Dr. Donna Culton describes the heterogenous presentation of bullous pemphigoid and how to diagnose this complicated disease.

Dr. Donna Culton discusses biomarkers in bullous pemphigoid and considers their potential clinical use.
Join Dr. Schmidt as he describes the pathophysiology of bullous pemphigoid, as well as novel research avenues to better understand this complicated disease.
Join Dr. Meijer as he highlights the signs and symptoms of bullous pemphigoid, and the importance of accurate and prompt diagnosis.
Dr Lawrence Eichenfield explores the broadening of treatment goals for long-term disease control, highlighting the importance of this approach in atopic dermatitis. Drs Culton, Elmariah, and Hawkes expand the discussion to further examine specific management goals unique to each skin disease (bullous pemphigoid, prurigo nodularis, and chronic spontaneous urticaria).
Join leading dermatologists for educational symposia on atopic dermatitis, bullous pemphigoid, and chronic spontaneous urticaria at the EADV congress in Paris, France.

Dr Jason Hawkes describes the importance of early intervention for patients with uncontrolled skin diseases and the effectiveness of evidence-based management strategies, sharing a patient case and his clinical insights with chronic spontaneous urticaria. Drs Eichenfield, Elmariah, and Culton join to review the burdens faced by patients with atopic dermatitis, prurigo nodularis, and bullous pemphigoid, respectively.
Dr Donna Culton walks through the pathophysiology of type 2 inflammation in inflammatory skin diseases, using bullous pemphigoid as an example. Drs Eichenfield, Elmariah, and Hawkes join to discuss the role of type 2 inflammation across atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, respectively.
This symposium delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. It highlights both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies through a series of engaging panel discussions with Drs Eichenfield, Elmariah, Culton, and Hawkes.
Follow Janet, a hypothetical patient, as she navigates the difficult journey of bullous pemphigoid, starting with symptom onset to diagnosis.
A static infographic detailing how autoimmunity and Type 2 inflammation play a critical role in the pathophysiology of Bullous Pemphigoid (BP).